Transcatheter aortic valve implantation (TAVI) has been proven to be the preferred procedure for patients with symptomatic aortic stenosis (AS) who do not qualify for surgery [1-2]. TAVI has been recently showed to present similar or even inferior all-cause mortality rates compared to surgery [3], thus representing a valid alternative also in the elderly [4]. Acute kidney injury (AKI) is one of the strongest predictors of mortality after TAVI and has been associated with worsened short- and long-term cardiovascular (CV) outcomes.
